Key terms
About TRVI
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good in March 2011 and is headquartered in New Haven, CT.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest TRVI news
Apr 09
6:05am ET
Understanding Analyst Recommendation Reports: A Guide to Effective Summaries
Mar 24
9:30pm ET
Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Oculis Holding (OCS) and Quanterix (QTRX)
Mar 22
8:05am ET
Buy Rating for Trevi Therapeutics Anchored on Haduvio’s Clinical Promise and Market Potential
Mar 21
7:50am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Vor Biopharma (VOR), Roche Holding AG (OtherRHHVF) and Trevi Therapeutics (TRVI)
Mar 21
7:27am ET
Trevi Therapeutics (TRVI) Receives a Buy from Stifel Nicolaus
Mar 21
6:10am ET
Analysts’ Top Healthcare Picks: Trevi Therapeutics (TRVI), Walgreens Boots Alliance (WBA)
Mar 20
4:07pm ET
Trevi Therapeutics reports Q4 EPS (8c), consensus (9c)
Feb 22
10:59am ET
Biotech Alert: Searches spiking for these stocks today
TRVI Financials
Key terms
Ad Feedback
TRVI Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
TRVI Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
